Research and Clinical Trials on Gabapentin (Neurontin, Gabarone)

Gabapentin (Neurontin, Gabarone) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Gabapentin (Neurontin, Gabarone).

• A Post-Marketing Clinical Pharmakokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
  Status: Not yet recruiting, Condition Summary: Renal Impairment
• Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
  Status: Recruiting, Condition Summary: Prostate Cancer
• Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain
  Status: Recruiting, Condition Summary: Post-traumatic Neuropathic Pain
• Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
  Status: Recruiting, Condition Summary: Benzodiazepine Dependence; Opioid Dependency
• The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section
  Status: Terminated, Condition Summary: Pain
• A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
  Status: Completed, Condition Summary: Postherpetic Neuralgia; Diabetic Neuropathy; Complex Regional Pain Syndrome; Carpal Tunnel Syndrome; HIV Neuropathy; Idiopathic Sensory Neuropathy; Peripheral Neuropathy
• Morphine COnsumption in Joint Replacement Patients, With and Without GaBapentin Treatment, a RandomIzed ControlLEd Study
  Status: Recruiting, Condition Summary: Postoperative Pain; Joint Replacement
• Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes in Breast Cancer Survivors
  Status: Recruiting, Condition Summary: Breast Cancer; Hot Flashes
• Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting
  Status: Enrolling by invitation, Condition Summary: Obesity, Morbid; Postoperative Pain; Postoperative Nausea and Vomiting
• Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion
  Status: Active, not recruiting, Condition Summary: Postoperative Pain
• A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions
  Status: Completed, Condition Summary: Healthy
• A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions
  Status: Completed, Condition Summary: Healthy
• A Limited Food Effect Study of Gabapentin 800 mg Tablets
  Status: Completed, Condition Summary: Healthy
• A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-Fasting Conditions
  Status: Completed, Condition Summary: Healthy
• A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions
  Status: Completed, Condition Summary: Healthy

 

Get These Clinical Trials as a Newsfeed

Gabapentin:             

Current Research Literature on Gabapentin (Neurontin, Gabarone)

Here are abstracts for some of the latest research articles to have appeared on Gabapentin (Neurontin, Gabarone):

SUNCT Syndrome Successfully Treated with the Combination of Oxcarbazepine and Gabapentin.

Pain Med. 2009 Oct 26;
Marziniak M, Breyer R, Evers S
ABSTRACT Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a syndrome of intermittent, brief, unilateral, severe paroxysms of orbital-temporal pain recurring multiple times per day. The pain modulation is often very difficult. The reported SUNCT patient is the first who responded to a combination treatment of oxcarbazepine and gabapentin.

Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats.

Epilepsia. 2009 Oct 27;
Cuellar-Herrera M, Peña F, Alcantara-Gonzalez D, Neri-Bazan L, Rocha L
Summary Purpose: To evaluate the effects of high-frequency electrical stimulation (HFS) in both ventral hippocampi, alone and combined with a subeffective dose of antiepileptic drugs, during the status epilepticus (SE) induced by lithium-pilocarpine (LP). Methods: Male Wistar rats, stereotactically implanted in both ventral hippocampi, were injected with pilocarpine (30 mg/kg, i.p.) 24 h after lithium (3 mEq/kg) administration. One minute following pilocarpine injection, HFS (pulses of 60 mus width at 130 Hz at subthreshold intensities and applied during 3 h) was applied alone or combined with subeffective doses of antiepileptic drugs. Results: HFS alone reduced the incidence of severe generalized seizures. This effect was not evident when HFS was combined with phenytoin (33.3 mg/kg, i.p.). HFS combined with diazepam (0.41 mg/kg, i.p.) or phenobarbital (10 mg/kg, i.p.) reduced the incidence of severe generalized seizures and mortality rate, and augmented the latency to first forelimb clonus, generalized seizure, and status epilepticus (SE). When combined with gabapentin (46 mg/kg, i.p.), HFS reduced the incidence of severe generalized seizures, enhanced latency to SE, and decreased mortality rate. Discussion: Subeffective doses of antiepileptic drugs that increase the gamma-aminobutyric acid (GABA)ergic neurotransmission may represent a therapeutic tool to augment the HFS-induced anticonvulsant effects.

[Efficacy of traditional herbal medicine Yokukansan on patients with neuropathic pain]

Masui. 2009 Oct; 58(10): 1248-55
Nakamura Y, Tajima K, Kawagoe I, Kanai M, Mitsuhata H
BACKGROUND: Neuropathic pain that is the chronic, severe, and intractable pain, interferes with activities of daily living (ADL) and consequently reduces quality of life (QOL). We reported the efficacy of Yokukansan in patients with neuropathic pain, including acute herpetic pain, postherpetic neuralgia, central poststroke pain, post-traumatic spinal cord injury pain, thalamic syndrome, complex regional pain syndrome and symptomatic trigeminal neuralgia. Yokukansan was more effective compared with traditional medicines, such as tricyclic antidepressants, carbamazepine, gabapentin, and opioids etc., which are recommended to treat neuropathic pain. Recently, effects of Yokukansan is reported on the behavioral and psychological symptoms of dementia (BPSD) in elderly patients with dementia. Repeated administration of Yokukansan decreases expression of 5-hydroxytryptamine (5-HT) 2A receptors in the prefrontal cortex in mice, and Yokukansan also protects destruction of myelin sheaths in rats with thiamine deficient-induced encephalopathy. Mechanism of effectiveness of Yokukansan on neuropathic pain has not been established; however, efficacy of Yokukansan on neuropathic pain has been shown clinically. CONCLUSIONS: As far as we know, this is the first report that Yokukansan was effective on neuropathic pain. Yokukansan without serious adverse reactions may be a possible medicine for treatment of neuropathic pain in future.

Pharmacokinetics of oral gabapentin in greyhound dogs.

Vet J. 2009 Oct 22;
Kukanich B, Cohen RL
The purpose of this study was to assess the pharmacokinetics of gabapentin in healthy greyhound dogs after single oral doses targeted at 10 and 20mg/kg PO. Six healthy greyhounds were enrolled (3 males, 3 females). Blood was obtained at predetermined times for the measurement of gabapentin plasma concentrations by liquid chromatography/mass spectrometry. Pharmacokinetic parameters were determined with computer software. The actual mean (and range) doses administered were 10.2 (9.1-12.0) mg/kg and 20.5 (18.2-24) mg/kg for the 10mg/kg and 20mg/kg targeted dose groups. The mean C(MAX) for the 10 and 20mg/kg groups were 8.54 and 13.22mug/mL at 1.3 and 1.5h, and the terminal half-lives were 3.3 and 3.4h, respectively. The relative bioavailability of the 10mg/kg group was 1.13 compared to the 20mg/kg group. Gabapentin was rapidly absorbed and eliminated in dogs, indicating that frequent dosing is needed to maintain minimum targeted plasma concentrations.

A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.

Anesth Analg. 2009 Nov; 109(5): 1645-50
Sen H, Sizlan A, Yanarates O, Emirkadi H, Ozkan S, Dagli G, Turan A
BACKGROUND: Gabapentin and ketamine are popular analgesic adjuvants for improving perioperative pain management. We designed this double-blind, placebo-controlled study to test and compare the preventive effects of perioperative ketamine and gabapentin on early and chronic pain after elective hysterectomy. METHODS: Sixty patients undergoing abdominal hysterectomy were randomly assigned to 1 of the following 3 groups: control group received oral placebo capsules and bolus plus infusion of saline; ketamine group received oral placebo capsules and, before incision, 0.3 mg/kg IV bolus and 0.05 mgxkg(-1)xh(-1) infusion of ketamine until the end of surgery; and gabapentin group received oral gabapentin 1.2 g and bolus plus infusion of saline. The anesthetic technique was standardized, and the postoperative assessments included verbal rating scales for pain and sedation, IV morphine usage, quality of recovery assessment, recovery of bowel function, resumption of normal activities, and patient satisfaction with their pain management. Patients were questioned at 1, 3, and 6 mo after surgery for chronic postoperative pain. RESULTS: Postoperative pain scores were significantly lower in the gabapentin group compared with the ketamine and control groups, and patient-controlled analgesia morphine use was significantly reduced in both treatment groups (versus control group) (P < 0.001). Total patient-controlled analgesia morphine use was decreased by 35% and 42% in the ketamine and gabapentin groups, respectively, compared with the control group (P < 0.001). Patient satisfaction with pain treatment was significantly improved in the ketamine and gabapentin groups compared with the control group (P < 0.001). The incidence of incisional pain and related pain scores at the 1-, 3-, and 6-mo follow-up were significantly lower in the gabapentin group compared with the ketamine and control groups (P < 0.001). CONCLUSION: Gabapentin and ketamine are similar in improving early pain control and in decreasing opioid consumption; however, gabapentin also prevented chronic pain in the first 6 postoperative months.